Active Specific Immunotherapy Against Adenocarcinomas

References

• Silverstein A M. The concept of immunological specificity. A History of Immunology. Academic Press, Harcourt Brace Jovanovich, San Diego 1989, chapter 12
   Google Scholar
• Scott O CA. Tumor transplantation and tumor immunity: A personal view. Cancer Res 1991; 51: 757–763
   PubMed Web of Science ®Google Scholar
• Old L J. Cancer immunology: The search for specificity—G. H. A. Clowes Memorial Lecture. Cancer Res 1981; 41: 361–375
   PubMed Web of Science ®Google Scholar
• Mitchell M S. Biomodulators in cancer treatment. J Clin Pharmacol 1992; 32: 2–9
   PubMed Web of Science ®Google Scholar
• Morton D L. Active immunotherapy against cancer: Present status. Semin Oncol 1986; 13: 180–185
   PubMed Web of Science ®Google Scholar
• Hasper M V, McCabe R P, Pomato N, et al. Coming full circle in the immunotherapy of colorectal cancer: Vaccination with autologous tumor cells—to human monoclonal antibodies—to development and application of a generic tumor vaccine. Human Tumor Antigens and Specific Tumor Therapy. Alan R Liss, New York 1989; 335–344
   Google Scholar
• MacLean G, McEwan A, Mackie E, . The potential of synthetic tumor-associated glycoconjugates (S-TAGs) for generating monoclonal antibodies for breast cancer imaging and for specific immunotherapy. Breast Cancer Immunodiagnosis and Immunotherapy, R L Ceriani, et al. Plenum Press, New York 1989; 3–11
   Google Scholar
• Oldham R K. Cancer and diabetes: Are there similarities?. Mol Biother 1990; 2: 130–131
   PubMedGoogle Scholar
• Hull S R, Bright A, Carraway K L, et al. Oligosaccharide differences in the DF3 sialomucin antigen from normal human nilk and the BT-20 human breast carcinoma cell line. Cancer Commun 1989; 1: 261–267
   PubMedGoogle Scholar
• Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: Overview and perspectives. Cancer Res 1985; 45: 2405–2414
   PubMed Web of Science ®Google Scholar
• Singhal A K. Histo-blood group antigens in cancer. Semin Cancer Biol 1991; 2: 379–388
   PubMedGoogle Scholar
• Ho S, Kim Y S. Carbohydrate antigens on cancer-associated mucin-like molecules. Semin Cancer Biol 1991; 2: 389–400
   PubMedGoogle Scholar
• Reddish M, Helbrecht N, Almeida A F, et al. Epitope mapping of CA27.29 within the protein core of the malignant breast carcinoma-associated mucin antigen, MUC-I. J Tumor Marker Oncol 1992; 7: 19–27
   Google Scholar
• Ding L, Lalani E N, Reddish M, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUCI mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUCI gene. Cancer Immunol Immunother 1992; 36: 9
   Web of Science ®Google Scholar
• Gendler S, Taylor-Popadimitriou J, Duhig T, et al. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263: 12820
   PubMed Web of Science ®Google Scholar
• Springer G F. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198–1206
   PubMed Web of Science ®Google Scholar
• Longenecker B M, Willans D J, MacLean G D, et al. Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J Natl Cancer Inst 1987; 78: 489–496
   PubMed Web of Science ®Google Scholar
• Samuel J, Noujaim A A, Maclean G D, et al. Analysis of human tumor associated Thomsen-Friedenreich antigen. Cancer Res 1990; 50: 4801–4808
   PubMed Web of Science ®Google Scholar
• Springer G F, Taylor C R, Howard D R, et al. Tn, a carcinoma-associated antigen, reacts with anti-Tn of normal human sera. Cancer 1985; 55: 561–569
   PubMed Web of Science ®Google Scholar
• Itzkowitz S H, Bloom E J, Kokal W A, et al. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66: 1960–1966
   PubMed Web of Science ®Google Scholar
• Yuan M, Itzkowitz S, Boland R, et al. Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry. Cancer Res 1986; 46: 4841–4847
   PubMed Web of Science ®Google Scholar
• Itzkowitz S, Yuan M, Montgomery C K, et al. Expression of Tn, sialosyl-Tn and T antigens in human colon cancer. Cancer Res 1989; 49: 197–204
   PubMed Web of Science ®Google Scholar
• Itzkowitz S, Kjeldsen T, Friera A, et al. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 1991; 100: 1691–1700
   PubMed Web of Science ®Google Scholar
• Coon J S, Weinstein R S, Summers J L. Blood group precursor T-antigen expression in human urinary blader carcinoma. American Journal of Clinical Pathology 1982; 77: 622–699
   PubMedGoogle Scholar
• Ohoka H, Shinomiya H, Yokoyama M, et al. Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody: A possible marker of recurrence. Urol Res 1985; 13: 47–50
   PubMed Web of Science ®Google Scholar
• Wolf M F, Ludwig A, Fritz P, et al. Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients. Tumor Biol 1988; 9: 190–194
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Terao T, Kawashima Y, et al. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992; 10: 95–101
   PubMed Web of Science ®Google Scholar
• MacLean G D, Longenecker B M. Clinical significance of the Thomsen-Friedenreich antigen. Semin Cancer Biol 1991; 2: 433–439
   PubMedGoogle Scholar
• Henningsson C M, Selvaraj S, MacLean G D, et al. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: Stimulation of anticancer T cell immunity in vivo. Cancer Immunol Immunother 1987; 25: 231–241
   PubMed Web of Science ®Google Scholar
• Fung P YS, Madej M, Koganty R R, et al. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990; 50: 4308–4314
   PubMed Web of Science ®Google Scholar
• North R J. Suppressor cells: T cells and macrophages. Immunity to Cancer, A E Reif, S Mitchell, F L Orlando. Academic Press. 1985; 239–251
   Google Scholar
• Fung P YS, Longenecker B M. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 1991; 51: 1170–176
   PubMed Web of Science ®Google Scholar
• Singhal A, Fohn M, Hakomori S. Induction of α-N-acetylgalacto-samine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy for active immunotherapy in mice. Cancer Res 1991; 51: 1406–1411
   PubMed Web of Science ®Google Scholar
• Berd D, Mastrangelo M J, Engstrom P F, et al. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982; 42: 4862–4866
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire H C, Mastrangelo M J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44: 5439–5443
   PubMed Web of Science ®Google Scholar
• Mastrangelo M J, Berd D, Maguire H. Cell-mediated immunity. The immunoaugmenting effects of cancer chemotherapeutic agents, semin Oncol 1986; 13: 186–194
   PubMed Web of Science ®Google Scholar
• Berd D, Mastrangelo M J. Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+, 2H4+ suppressor-induced t-cells. Cancer Res 1988; 48: 1671–1675
   PubMed Web of Science ®Google Scholar
• Sahasrabudhe D M, de Kernion J B, Pontes J E, et al. Specific immunotherapy with supressor function inhibition for metastatic renal cell carcinoma. J Biol Resp Modif 1986; 5: 581–594
   PubMedGoogle Scholar
• Hoon D SB, Foshag L J, Nizze A S, et al. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990; 50: 5358–5364
   PubMed Web of Science ®Google Scholar
• Hoover S K, Barrett S K, Turk T MT, et al. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol Immunother 1990; 31: 121–127
   PubMed Web of Science ®Google Scholar
• Oratz R, Dugan M, Roses D F, et al. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Cancer Res 1991; 51: 3643–3647
   PubMed Web of Science ®Google Scholar
• Livingston P O, Natoli E J, Calves M J, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84: 2911–2915
   PubMed Web of Science ®Google Scholar
• Brockmeyer N H, Kreuzfelder E, Bluhm C, et al. Immunomodulation of cimetidine in healthy volunteers. Klin Wochenschr 1989; 67: 26–30
   PubMedGoogle Scholar
• Ziegler-Heitbrock H W, Stachel D, Schlunk T, et al. Class II (DR) antigen expression on CD8+ lymphocyte subsets in acquired immune deficiency syndrome (AIDS). J Clin Immunol 1988; 8: 473–478
   PubMed Web of Science ®Google Scholar
• Deem R L, Targan S R, Niederlehner A, et al. The CD8+ Leu7+ subset of T cells in Crohn's disease: Distinction between cytotoxic and covert suppressor functions. Clin Exp Immunol 1990; 80: 387–394
   PubMed Web of Science ®Google Scholar
• Morio T, Takase K, Okawa H, et al. The increase of non-MHC-restricted cytotoxic cells (gamma/delta-TCR-bearing T cells or NK cells) and the abnormal differentiation of B cells in Wiskott-Aldrich syndrome. Clin Immunol Immunopathol 1989; 52: 279–290
   PubMedGoogle Scholar
• Yabe H, Yabe M, Kato S, et al. Increased numbers of CD8+ CD11+, CD8+ CD11- and CD8+ Leu7+ cells in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5: 295–300
   PubMed Web of Science ®Google Scholar
• Vinci G, Bernant J P, Nakazawa M, et al. In-vitro inhibition of normal human hematopoiesis by marrow CD3-positive CD8-positive HLA-DR-positive HNK-1-positive lymphocytes. Blood 1988; 72: 1616
   PubMed Web of Science ®Google Scholar
• Hanna M G, Peters L C. Immunotherapy of established micrometastases with bacillus Calmette-Guérin tumor cell vaccine. Cancer Res 1978; 38: 204–209
   PubMed Web of Science ®Google Scholar
• Hoover H C, Surdyke M G, Dangel R B, et al. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985; 55: 1236–1243
   PubMed Web of Science ®Google Scholar
• Hanna M G, Hoover H C. Active specific immunotherapy as an adjunct to the treatment of metastatic solid tumors. Immunity to Cancer. Academic Press, Orlando, FL 1985; 429–442
   Google Scholar
• Hanna M G, Peters L C, Haspel M V, . Fundamental and applied aspects of successful active specific immunotherapy of cancer. Principles of Cancer Biotherapy, 2nd ed, R K Oldham, et al. Raven Press, New York 1987; 253–283
   Google Scholar
• Wallack M K, Steplewski Z, Koprowski H, et al. A new approach in specific, active immunotherapy. Cancer 1977; 39: 560–564
   PubMed Web of Science ®Google Scholar
• Wallack M K, Bash J, Bartolucci A. Improvement in disease-free survival of melanoma patients in conjunction with serologic response in a phase Ia/Ib Southeastern Cancer Study Group trial of vaccinia melanoma oncolysate. Am Surg 1989; 55: 244–247
   Google Scholar
• Arroyo P J, Bash J A, Wallack M K. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferona in a murine hepatic metastasis model. Cancer Immunol Immunother 1990; 31: 305–311
   PubMed Web of Science ®Google Scholar
• Freedman R S, Edwards C L, Bowen J M, et al. Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 1988; 29: 337–347
   PubMed Web of Science ®Google Scholar
• Furukawa K, Lotzova E, Freedman R S, et al. Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer. Cancer Immunol Immunother 1989; 30: 126–132
   PubMed Web of Science ®Google Scholar
• Ioannides C G, Platsoucas C D, O'Brian C A, et al. Viral oncolysates in cancer treatment: Immunological mechanisms of action (review). Anticancer Res 1989; 9: 535–544
   PubMed Web of Science ®Google Scholar
• Ioannides C G, Platsoucas C D, Patenia R, et al. T-cell functions in ovarian cancer patients treated wtih viral oncolysates: I. Increased helper activity to immunoglobulin production. Anticancer Res 1990; 10: 645–654
   PubMed Web of Science ®Google Scholar
• Wolfram B, Schlag P, Liebrich W, et al. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine (first clinical results with tumor-cell vaccines modified with live but avirulent New-castle disease virus). Cancer 1990; 66: 1517–1523
   PubMed Web of Science ®Google Scholar
• Hollinshead A, Elias E G, Arlen M, et al. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). Cancer 1985; 56: 480–489
   PubMed Web of Science ®Google Scholar
• Stewart T HM, Shelley W E, Willan A R, et al. An evaluation of the role of tumor-specific antigens. Annu Clin Conf Cancer 1986; 28: 351–374
   Google Scholar
• Hollinshead A, Stewart T HM, Takita H, et al. Adjuvant specific active lung cancer immunotherapy trials. Cancer 1987; 60: 1249–1262
   PubMed Web of Science ®Google Scholar
• McCune C S, Schapira D V, Henshaw E C, et al. Specific immunotherapy of advanced renal carcinoma: Evidence for the polyclonality of metastases. Cancer 1981; 47: 1984–1987
   PubMed Web of Science ®Google Scholar
• Kurth K H, Marquet R, Zwartendijk J, . Active, specific immunotherapy with autologous tumor cells and mixed with Corynebacterium parvum in patients with metastatic renal cell carcinoma. Proc. Int. Symp. Nonnweiler, Present Status of Non-toxic Concepts in Cancer, K F Klippel, E Macher, et al. Karger, Basel, New York 1986; 221–236
   Google Scholar
• Swanson M A, Schwartz R S. Immunosuppressive therapy. The relation between clinical response and immunologic competence. N Engl J Med 1967; 277: 163–170
   PubMed Web of Science ®Google Scholar
• Mitchell M, Kan-Mitchell J, Kempf R A, et al. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48: 5883–5893
   PubMed Web of Science ®Google Scholar
• Mitchell M, Harel W, Kempf R A, et al. Active specific immunotherapy for melanoma. J Clin Oncol 1990; 8: 856–869
   PubMed Web of Science ®Google Scholar
• McCune C. Interleukin-1 as an adjuvant for tumor vaccine increases survival in mice. Biotherapy 1989; 1: 355–359
   PubMedGoogle Scholar
• Adachi M, Suzuki Y, Ietomi K, et al. Active immunization of human cancer with tumor cell-associated carbohydrate antigen. Anticancer Res 1989; 9: 309–312
   PubMed Web of Science ®Google Scholar
• MacLean G D, Bowen-Yacyshyn M B, Samuel J, et al. Active-immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 1992; 11: 292–305
   PubMed Web of Science ®Google Scholar
• Hanna M G, Key M E. Immunotherapy of metastases enhances subsequent chemotherapy. Science 1982; 217: 367–369
   PubMed Web of Science ®Google Scholar